drugset / Trial / NCT06759090
Metronomic Capecitabine with Camrelizumab and Apatinib Mesylate for Treatment of Advanced Pancreatic Cancer
NaSingle-groupOpen-labelTreatment
Summary
This study is a multicenter, single-arm, phase II exploratory study, aims to evaluate the efficacy and safety of metronomic capecitabine with camrelizumab and apatinib mesylate in advanced pancreatic cancer after the failure of first-line treatment.
Timeline
- Start
- 2025-01-15
- Primary completion
- 2027-01-15
- Completion
- 2028-06-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Camrelizumab | Monoclonal antibody | 200 mg | Intravenous |
| Subject | Capecitabine | Small molecule | 650 mg/m2 | Oral |
| Subject | Rivoceranib | Small molecule | 250 mg | Oral |